Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: A systematic review of cohort studies with focus on dose

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 2, 2013, Pages 144-151

  Eng, Grith ^a   Stoltenberg, Michael B ^a   Szkudlarek, Marcin ^a   Bouchelouche, Pierre N ^a   Christensen, Robin ^a   Bliddal, Henning ^a   Marie Bartels, Else ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

Adalimumab; Dose escalation; Etanercept; Infliximab; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ADULT; ARTICLE; COHORT ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADALIMUMAB; DOSE ESCALATION; ETANERCEPT; INFLIXIMAB; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84886101336     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.01.007     Document Type: Article

References (28)

1. Smolen J.S., Landewe R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
2. Danish Society of Rheumatology. Clinical guideline for the diagnosis, classification, treatment and monitoring of rheumatoid arthritis, [accessed 12.06.12]. http://www.danskreumatologiskselskab.dk.
3. Blom M., Kievit W., Kuper H.H., Jansen T.L., Visser H., den Broeder A.A., et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res 2010, 62:1335-1341. [Hoboken].
4. Schabert V.F., Bruce B., Ferrufino C.F., Globe D.R., Harrison D.J., Lingala B., et al. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin 2012, 28:569-580.
5. Ariza-Ariza R., Navarro-Sarabia F., Hernandez-Cruz B., Rodriguez-Arboleya L., Navarro-Compan V., Toyos J. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology 2007, 46:529-532. [Oxford].
6. Stern R., Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004, 31:1538-1545.
7. Abbott Laboratories. Humira (adalimumab) full prescribing information, [accessed 07.06.12]. http://www.rxabbott.com/pdf/humira.pdf.
8. Amgen Inc. Enbrel (etanercept) full prescribing information, [accessed 07.06.12]. http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf.
9. Janssen Biotech Inc. Remicade (infliximab) full prescribing information, [accessed 07.06.12]. http://www.remicade.com/hcp/remicade/assets/hcp_ppi.pdf.
10. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. http://www.cochrane-handbook.org.
11. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
12. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
13. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van V.R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
14. Weinblatt M.E., Schiff M.H., Ruderman E.M., Bingham C.O., Li J., Louie J., et al. Efficacy and safety of etanercept 50mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50mg once a week-Results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008, 58:1921-1930.
15. van Vollenhoven R.F., Brannemark S., Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004, 63:426-430.
16. Pavelka K., Jarosova K., Suchy D., Senolt L., Chroust K., Dusek L., et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009, 68:1285-1289.
17. Fernandez-Nebro A., Irigoyen M.V., Urena I., Belmonte-Lopez M.A., Coret V., Jimenez-Nunez F.G., et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol 2007, 34:2334-2342.
18. Flendrie M., Creemers M.C., van Riel P.L. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology 2007, 46:146-149. [Oxford].
19. Takeuchi T., Miyasaka N., Inoue K., Abe T., Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 2009, 19:478-487.
20. Durez P., Van den B.F., Corluy L., Veys E.M., De C.L., Peretz A., et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology 2005, 44:465-468. [Oxford].
21. Edrees A.F., Misra S.N., Abdou N.I. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 2005, 23:469-474.
22. Rahman M.U., Strusberg I., Geusens P., Berman A., Yocum D., Baker D., et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:1233-1238.
23. St Clair E.W., Wagner C.L., Fasanmade A.A., Wang B., Schaible T., Kavanaugh A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:1451-1459.
24. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., van Riel P.L., et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745.
25. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., van Schouwenburg P.A., Lems W.F., Twisk J.W., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. J Am Med Assoc 2011, 305:1460-1468.
26. Westhovens R., Yocum D., Han J., Berman A., Strusberg I., Geusens P., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006, 54:1075-1086.
27. Klarenbeek N.B., Guler-Yuksel M., van der Kooij S.M., Han K.H., Ronday H.K., Kerstens P.J., et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011, 70:1039-1046.
28. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926.